SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (871)8/3/1999 9:31:00 AM
From: Rick Strange  Read Replies (1) | Respond to of 1386
 
According to the Company, the market for dexanabinol in the treatment for severe head trauma may reach $500 million a year and could reach $1 billion if other neurological conditions such as stroke are included. In the U.S. about 370,00 severe head trauma patients are hospitalized each year. World wide more than twice that amount.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News